Korean J Ophthalmol > Volume 38(5); 2024 > Article
Moon, Kim, and Cho: Two-year Outcomes of Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration with “Observe before Treat-and-Extend” Method

Abstract

Purpose

To evaluate 2-year outcomes of intravitreal aflibercept injection for neovascular age-related macular degeneration (nAMD) treated with “observe before treat-and-extend (O-TAE)” strategy in the real-world setting.

Methods

This retrospective study included treatment-naive nAMD patients treated with aflibercept using O-TAE regimen and followed up for more than 2 years. Patients were observed bimonthly to check recurrence after three monthly loading injections. In case of recurrence, treatment was resumed using the TAE regimen starting from the fourth injection. In case of nonrecurrence, observation was continued. Best-corrected visual acuity (BCVA), central macular thickness (CMT), number of injections, TAE intervals, and proportion of recurrence after dry-up following three loadings were analyzed.

Results

A total of 38 eyes of 34 patients were included. Follow-up period was 37.0 ± 11.0 months. BCVA by logarithm of minimal angle of resolution improved from 0.33 ± 0.29 at baseline to 0.24 ± 0.23 in the first year (p = 0.010) and 0.25 ± 0.22 in the second year (p = 0.054). CMT decreased significantly from 357.43 ± 74.53 μm at baseline to 269.62 ± 48.12 μm in the first year (p < 0.001) and 279.14 ± 54.64 μm in the second year (p < 0.001). Number of injections were 5.11 ± 1.69 in the first year and 3.84 ± 2.39 in the second year. The percentage of eyes with a TAE interval of ≥12 weeks was 37.0% in the first year and 34.4% in the second year. Of the 36 eyes that dried up after three loadings, 28 eyes (77.8%) recurred, and the average period of recurrence was 6.5 months. The remaining eight eyes (22.2%) had no recurrence during the mean follow-up period of 29.7 months.

Conclusions

This study showed that the newly suggested O-TAE strategy can reduce the treatment burden significantly reducing the number of injections while improving BCVA and CMT in the first and second year.

Neovascular age-related macular degeneration (nAMD) is one of the leading causes of vision loss worldwide [1]. Despite many studies have shown great treatment results for nAMD with the introduction of anti-vascular endothelial growth factor (anti-VEGF) therapy [2-4], the high cost of the drugs and frequent visits place a burden to patients [5].
Subsequently, treatment regimens such as pro re nata (PRN, as needed) and treat-and-extend (TAE) were introduced. The PRN method requires monthly follow-up visit and injections in case of recurrence. There were reports that it was difficult to maintain improvement in vision if monthly follow-up visits were not made [6-8]. As an alternative, the TAE regimen was proposed to maintain vision improvement while reducing the inconvenience of monthly visits and the number of injections [9-11]. Several studies have reported that the TAE method has a vision improvement effect similar to monthly injections and can reduce the number of visits [12-14]. As such, TAE strategy is widely used as a treatment schedule for nAMD [15].
Here, we introduce “observe before TAE (O-TAE)” regimen for treatment of nAMD. The O-TAE regimen is a modification of TAE that has an observation period to detect recurrence before starting TAE. Although there are several studies reported long-term clinical real-world results for aflibercept using conventional TAE therapy in nAMD [16-20], there has been few reports on clinical outcomes of O-TAE strategy in nAMD. Jeong et al. [21] suggested a similar strategy called “modified observe-and-plan” regimen according to the individual recurrence interval in a 1-year follow-up retrospective study. The purpose of the present study was to evaluate 2-year clinical outcomes of intravitreal aflibercept injection for nAMD treated with O-TAE strategy.

Materials and Methods

Ethics statement

This study was approved by the Institutional Review Board of Ewha Womans University Medical Center (No. 2024-05-048). The requirement of informed consent was waived due to the retrospective nature of the study. The authors adhered to the tenets of the Declaration of Helsinki throughout the study.

Study design

This was a single centered, retrospective cohort study.

Study population

Inclusion criteria was as follows: (1) patients who were diagnosed with nAMD from March 1, 2019, to May 31, 2022, and treated with intravitreal aflibercept injections at our medical center (Ewha Womans University Mokdong Hospital, Seoul, Korea; and Ewha Womans University Seoul Hospital, Seoul, Korea); (2) treatment-naive patients; (3) treated with O-TAE strategy; and (4) followed up more than 2 years (i.e. the possible latest follow-up was May 31, 2024).
In order to extract cases that met the above inclusion criteria, we proceeded in the order of the flowchart in Fig. 1. First, using clinical data warehouse search, we retrieved the cases of intravitreal aflibercept injections performed from March 1, 2019, to July 31, 2022. A total of 1,750 cases were extracted. Among these, duplicate patients were removed based on registration number, leaving only one for each duplicate case; 388 patients remained. By searching their electronic medical records, 189 eyes of 178 patients with confirmed diagnosis of nAMD were extracted. Among the 189 eyes, 151 eyes were excluded. Exclusion criteria were the following: (1) previous history of nAMD treatment (anti-VEGF, laser, or photodynamic therapy; n = 72); (2) follow-up period of less than 2 years (n = 26); (3) regimen other than O-TAE (n = 15); (4) started treatment with bevacizumab or ranibizumab (n = 14); (5) switched to other anti-VEGF (n = 12); (6) cataract operation during follow- up periods (n = 6); (7) vitrectomy history or vitrectomy during follow-up periods (n = 5); and (8) other ocular disease of affecting visual acuity (n = 1). The remaining 38 eyes were finally enrolled and analyzed in the study.

Treatment strategy and subgroups

Here, we suggest a so-called O-TAE regimen. Patients included in the study received three monthly loading intra-vitreal injections of aflibercept 2 mg/0.05 mL (Eylea, Bayer Pharma) for nAMD. Patients were observed bimonthly to check recurrence. The recurrence was defined as new retinal hemorrhage or presence of subretinal and/or intraretinal fluid on spectral-domain optical coherence tomography (OCT; Spectralis, Heidelberg Engineering). In case of recurrence or if fluid remains after three loading injections, treatment was resumed using the TAE regimen starting from the fourth injection. In cases where there was no recurrence, follow-up observation was continued. When starting the TAE regimen, the injection interval started from 8 weeks and was adjusted by 2 weeks depending on whether there was recurrence. The injection interval was extended by 2 weeks without recurrence and shortened by 2 weeks with recurrence. In the present study, there were some cases without recurrence after three loading injections. Cases that started the TAE regimen were divided into two subgroups according to the minimum and maximum TAE intervals chosen by two physicians (SCC and HJK): group A with TAE interval from a minimum of 8 weeks to a maximum of 12 weeks and group B with TAE interval from a minimum of 4 weeks to a maximum of 16 weeks.

Clinical outcome measurements

At each visit, all patients underwent complete eye examinations, including measurement of the best-corrected visual acuity (BCVA; decimal values) and intraocular pressure, slit-lamp biomicroscopy, dilated fundus examinations, wide fundus photography (Nikon, Optos California), and OCT. Central macular thickness (CMT) was measured at each visit by OCT. The diagnosis of nAMD was confirmed with dilated fundus examination or wide fundus photography, OCT, fluorescein angiography, and indocyanine green angiography. BCVA, CMT, number of injections, TAE intervals, proportion of recurrence after drying up following three loading injections, average time to recurrence, and average follow-up period for nonrecurrence were analyzed.

Statistical analysis

Statistical analyses were performed using IBM SPSS ver. 27.0 (IBM Corp). The data are presented as the mean ± standard deviation. The BCVAs were converted to logarithm of the minimal angle of resolution (logMAR) for analysis. The BCVA and CMT were compared between baseline and the first or the second year using the Wilcoxon signed rank test. The Mann-Whitney U-test was used to analyze the difference between group A and group B. A p-value of 0.05 denoted statistically significance.

Results

A total of 38 eyes of 34 patients (21 men, 13 women) with treatment-naive nAMD were included. The mean age of the included patients was 72.0 ± 9.8 years. Baseline mean BCVA by logMAR was 0.33 ± 0.29 and baseline mean CMT was 357.43 ± 74.53 μm. Of the total 38 eyes, 28 eyes were typical nAMD and the remaining 10 eyes were polypoidal choroidal vasculopathy (PCV). All of the nine eyes of retinal angiomatous proliferation met the exclusion criteria and were not included in the study. The remaining demographic data are presented in Table 1. For a total of 30 eyes, the TAE regimen was started. Among these, one case which recurred 34.3 months after 3 loading injections was excluded from the subgroup analysis. Finally, 18 eyes were classified as group A and 11 eyes were classified as group B. Except for lens status, there were no significant differences in baseline factors between group A and group B (Supplementary Table 1). The proportion of phakic lenses was relatively higher in group A than in group B (p = 0.048).
For the total 38 eyes, the BCVA improved significantly in the first year and improved by marginal significance in the second year, compared with the baseline (Table 2 and Fig. 2). The BCVA by logMAR improved from 0.33 ± 0.29 at baseline to 0.24 ± 0.23 in the first year (p = 0.010), and 0.25 ± 0.22 in the second year (p = 0.054). There was no significant difference in BCVA between group A and group B at baseline, first year, and second years. Among the 10 eyes of PCV patients, none showed severe deterioration signs such as submacular hemorrhage or breakthrough hemorrhage.
The CMT decreased significantly in the first year, and second year compared with the baseline (Table 3 and Fig. 3). The CMT decreased significantly from 357.43 ± 74.53 μm at baseline to 269.62 ± 48.12 μm in the first year ( p < 0.001), and 279.14 ± 54.64 μm in the second year (p < 0.001). There was no significant difference in CMT between group A and B at baseline, 1 year, and 2 years.
The number of injections until the first year of follow-up was 5.11 ± 1.69 and the number of injections from the first to the second year of follow-up was 3.84 ± 2.39 (Table 4 and Fig. 4). The number of injections in the second year was significantly lower than in the first year (p < 0.001). There was no significant difference in the number of injections between group A and B in the first and second year. There was no significant difference in the number of injections between the eyes with typical nAMD and PCV in the first and second year (Supplementary Table 2).
When groups A and B were combined, the proportions of TAE interval were as shown in Fig. 5. In the second year, the percentage of eyes with a TAE interval of 8, 9-11, 12-15, and 16 weeks was 34.5%, 31.0%, 31.0%, and 3.4%, respectively. The percentage of eyes with a TAE interval of 12 weeks or more was 37.0% in the first year and 34.4% in the second year.
Among the total of 38 eyes, 36 eyes (94.7%) dried up (i.e., had no intraretinal or subretinal fluid) after 3 loading injections, and the remaining two eyes (5.3%) had some fluid (Table 5). Of the 36 eyes that dried up, 28 eyes (77.8%) recurred and the average period from the third loading injection to the recurrence was 6.5 ± 7.1 months. Of the 36 eyes that dried up, eight eyes (22.2%) had no recurrence during a mean follow-up period of 29.7 ± 8.1 months covering the third loading injection to the last follow-up. There was no significant difference in the proportion of the recurrence after dry-up nor in mean recurrence time between typical nAMD and PCV (Supplementary Table 3). None of the baseline factors was correlated with the recurrence after dry-up following three loading injections (Supplementary Table 4).

Discussion

In this study, O-TAE strategy showed improvement in BCVA and CMT in the first and second year compared to the baseline. The average number of injections was 5.1 in the first year and 3.8 in the second year. The percentage of eyes with a TAE interval of 12 weeks or more was 37.0% in the first year and 34.4% in the second year. Of the 36 eyes that dried up after three loading injections, 28 eyes (77.8%) recurred and the average period to recurrence was 6.5 months. The remaining eight eyes (22.2%) had no recurrence during the mean follow-up period of 29.7 months. None of the baseline factors was correlated with the recurrence.
In addition to the conventional standard TAE [22-24], various modified treatment regimens were introduced in the previous studies [21,25-30] (Table 6 and Fig. 6A-6E). “Modified TAE” regimens for nAMD were described in previous studies [25-27]. Ohnaka et al. [25] introduced modified TAE regimen, which consists of an induction phase, an observation phase, and a TAE phase (Fig. 6B). During the induction phase, patients received ≥3 monthly intravitreal aflibercept loading injections until no signs of disease activity. Patients were monitored monthly until disease activity appeared to determine the “recurrence interval” during the observation phase. The recurrence interval was defined as the time from when no signs of disease activity was achieved during the induction phase to when the first signs of recurrence appeared. During TAE phase, patients received monthly injections until no signs of disease activity. Then, the next injection was administered after initial “treatment interval” which was reduced by 2 weeks from the recurrence interval. Subsequent injections were administered with an interval reduced by 2 weeks for occasions with disease activity, and with an interval increased by 2 weeks for cases without disease activity [25]. “Observe-and-plan” regimen for treatment of nAMD was described first in the study on ranibizumab by Mantel et al. [28] and analyzed later in the study on aflibercept by Parvin et al. [29] and Subhi et al. [30]. After three loading injections, a monthly observation visit was conducted to determine the recurrence interval. Then, the recurrence interval was reduced by 2 weeks to determine the retreatment interval for the next two or three injections without intermittent ophthalmic examination during “treatment plan” phase (Fig. 6C) [28,29]. The available choice of retreatment intervals was limited to 1 to 3 months. Recurrences that were observed at ≥4 months since last injection was an indication to treat every 3 months. Follow-up assessment visits were performed with the same interval from the last injection of the “treatment plan.” The adjustment of the intervals in the subsequent treatment plans was performed according to the disease activity (Fig. 6C). Compared to the “modified TAE” or “observe-and-plan,” our O-TAE regimen is different in that observation was performed every 2 months after the third injection, and if recurrence occurred, TAE was started from the fourth injection with the treatment interval of 8 weeks. Jeong et al. [21] suggested a “modified observe-and-plan” strategy according to the interval of individual recurrence in a 1-year follow-up retrospective study (Fig. 6D). After three monthly loading injections of aflibercept, all patients were monitored monthly during the observation phase to determine whether a dry macula was attained in their study. Patients who showed exudative activity within 3 months were categorized to early-recurrence group. The other patients were allocated to the late-recurrence group. The early-recurrence group was treated with TAE regimen with adjusted interval of 2 weeks within 8 to 12 weeks. The late-recurrence group was treated as needed. TAE was applied only to the early-recurrence group showing disease activity within 3 months after 3 monthly loading injections in their study. Our O-TAE regimen is different from the “modified observe-and-plan” in that if recurrence occurred, TAE was started from the fourth injection regardless of the time of recurrence (Fig. 6E). Our study is also different in that patients were observed after three monthly loading injections with an interval of 2 months until recurrence (Fig. 6E). Comparison of the conventional TAE and other modified variations of the treatment regimen is summarized in Table 6 [21-30] and Fig. 6.
In the current study, BCVA and CMT improved in the first and second year compared to the baseline. There have been few previous studies on O-TAE analyzed in our study. It can be said that the method applied to the early-recurrence group of the “modified observe-and-plan” by Jeong et al. [21] is similar to the O-TAE regimen of our study. As in our study, BCVA and CMT were significantly improved in the first year, compared to the baseline in their study.
The mean number of injections was 5.1 ± 1.7 in the first year and 3.8 ± 2.4 in the second year in our study. This is lower than that of conventional TAE. Ishibashi et al. [19] reported retrospective study result of 4-year outcomes of intravitreal aflibercept injection for nAMD using TAE regimen in Japan in 39 eyes of 39 patients. TAE interval ranged from a minimum of 4 weeks to a maximum of 20 weeks in their study. BCVA and CMT improved significantly compared to baseline and was maintained until the fourth year in the study. The average number of injections was 7.9, 6.0, 5.5, and 5.4 in the first, second, third, and fourth year, respectively. The mean number of injections in the first and second year was lower in our study than in their study. Choi et al. [31] reported 1-year outcomes of the intravitreal aflibercept using TAE method in 36 treatment- naive nAMD in Korean population. The treatment interval was shortened or extended to a minimum of 8 weeks and a maximum of 16 weeks depending on disease activity. The average number of injections per year was 6.8 ± 0.5 in their study. The mean number of injections in the first year was lower in our study than in their study. In our O-TAE regimen, instead of immediately starting the fourth injection with TAE after 2 months following three loading injections, there was an observation phase to check recurrence after three monthly loadings. Therefore, the mean number of injections in the first and second year is reduced compared to the conventional TAE. As shown in Table 5, after drying up with three loading injections, recurrence did not occur in 22.2%, which presumably lowered the overall average number of injections. The significance of O-TAE is that it can reduce the treatment burden by significantly reducing the number of injections while improving BCVA and CMT.
In the current study, the percentage of eyes with a TAE interval of 12 weeks or more was 37.0% in the first year and 34.4% in the second year. In the study of Jeong et al. [21] which applied a strategy similar to our O-TAE regimen in their early-recurrence group, the percentages of patients with a TAE interval of 12 weeks were 25.0% in the early-recurrence group. In the study of Ishibashi et al. [19], the percentage of patients with a TAE interval of 12 weeks or more was 46.2%, 46.2%, 43.6%, and 46.2% in the first, second, third, and fourth year, respectively. In our study, TAE interval ranged from 8 to 12 weeks in group A and from 4 to 16 weeks in group B. In the study of Jeong et al. [21], TAE interval ranged from 8 to 12 weeks. In the study of Ishibashi et al. [19], TAE interval ranged from 4 to 20 weeks. These differences could be attributed to the difference in the above proportions among our study and theirs.
Out of the 36 eyes which dried up after three loading injections, eight eyes (22.2%) did not recur during an average follow-up period of 29.7 ± 8.1 months. This suggests that there is a certain proportion of patients who are stabilized without recurrence for a considerable period of time after three loading injections. This can be a clinical basis for having an observation period to check for recurrence after three monthly loading injections. If TAE is applied to these stable patients, there is a possibility of overtreatment. Among the 36 eyes which dried up after three loadings, the remaining 28 eyes (77.8%) recurred, taking an average of 6.5 ± 7.1 months until recurrence. In the study of Inoue et al. [32], the median period from the third loading injection to retreatment was 5 months. The range of period until recurrence after third loading injection was 1.9 to 34.3 months in our study, suggesting that long-term follow-up is important for nAMD. In the present study, among eyes which dried up after three loadings, there were no significant baseline factors between the recurrence group and the nonrecurrence group. In the study of Jeong et al. [21], no significant differences in the baseline characteristics were observed between the early- and late-recurrence groups. In the study of Kikushima et al. [33], older age and T-allele of ARMS2 A69S (rs10490924) were significant factors associated with retreatment after three loading injections. In the current study, age was not a significant factor in the recurrence. Genetic analysis was not performed in our study.
This study has several limitations. First, this study had a retrospective design and had an inherent risk of selection bias. The adjustment of TAE interval was not consistently unified and was performed according to the preferences of each physician. Nevertheless, the BCVA, CMT, number of injections were not significantly different between group A and group B. Second, the size of the study samples is small. However, by extracting data by combining clinical data warehouse and electronic medical records using the method described in the method section, the study populations in the current study were selected, without data loss from the entire neovascular AMD cohort diagnosed and treated at our medical center. In addition, exclusion criteria including treatment naïve cases were strictly applied through a thorough review of electronic medical records. Lastly, the entire population of this study was Korean, indicating that the results of the current study may not be applicable to the population of other ethnicities. The strength of this study is the investigation of the real-world outcomes of the O-TAE strategy for nAMD, which has not been studied well previously. Longer term studies with a larger number of patients on the clinical outcomes of O-TAE regimen are needed.
In conclusion, the 2-year long-term results of intravitreal aflibercept injection with O-TAE strategy showed effectiveness with functional and anatomical improvement for nAMD. In addition, O-TAE regimen was able to reduce the number of injections compared to conventional TAE. O-TAE strategy could be considered as an alternative in the treatment of nAMD.

Acknowledgements

None.

Notes

Conflicts of Interest

None.

Funding

None.

Supplementary Materials

Supplementary materials are available from https://doi.org/10.3341/kjo.2024.0083.
Supplementary Table 1. Baseline characteristics and demographics between the two subgroups
kjo-2024-0083-Supplementary-Table-1.pdf
Supplementary Table 2. Number of injections in the first and second year according to the subtypes of nAMD
kjo-2024-0083-Supplementary-Table-2.pdf
Supplementary Table 3. Dry-up after three loading injections and recurrence after dry-up, according to the subtypes of nAMD
kjo-2024-0083-Supplementary-Table-3.pdf
Supplementary Table 4. Univariate and multivariate logistic regression analysis of variables for recurrence after three monthly aflibercept loading injections
kjo-2024-0083-Supplementary-Table-4.pdf

References

1. GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health 2021;9:e144-60.
pmid
2. Sarwar S, Clearfield E, Soliman MK, et al. Aflibercept for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2016;2:CD011346.
crossref pmid
3. CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908.
crossref pmid pmc
4. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
crossref pmid
5. Brown GC, Brown MM, Rapuano SB, Boyer D. A cost-benefit analysis of VEGF-inhibitor therapy for neovascular age-related macular degeneration in the United States. Am J Ophthalmol 2021;223:405-29.
crossref pmid
6. Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 2015;99:220-6.
crossref pmid pmc
7. Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group. The neovascular age-related macular degeneration database: multicenter study of 92, 976 ranibizumab injections: report 1: visual acuity. Ophthalmology 2014;121:1092-101.
crossref pmid
8. Lad EM, Hammill BG, Qualls LG, et al. Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries. Am J Ophthalmol 2014;158:537-43.
crossref pmid
9. Spaide R. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol 2007;143:679-80.
crossref pmid
10. Stewart MW. Individualized treatment of neovascular age-related macular degeneration: what are patients gaining? or losing? J Clin Med 2015;4:1079-101.
crossref pmid pmc
11. Freund KB, Korobelnik JF, Devenyi R, et al. Treat-and-extend regimens with anti-VEGF agents in retinal diseases: a literature review and consensus recommendations. Retina 2015;35:1489-506.
pmid
12. Augsburger M, Sarra GM, Imesch P. Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study. Graefes Arch Clin Exp Ophthalmol 2019;257:1889-95.
crossref pmid pdf
13. Hatz K, Prunte C. Treat and extend versus pro re nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 Month study. Acta Ophthalmol 2017;95:e67-72.
crossref pmid pdf
14. Chin-Yee D, Eck T, Fowler S, et al. A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. Br J Ophthalmol 2016;100:914-7.
crossref pmid
15. Khachigian LM, Liew G, Teo KY, et al. Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration. J Transl Med 2023;21:133.
crossref pmid pmc pdf
16. Huang CH, Lai TT, Yang CH, Hsieh YT. Two-year real- world results for aflibercept using the treat-and-extend regimen in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Ophthalmol Ther 2024;13:385-96.
crossref pmid pmc pdf
17. Jaggi D, Nagamany T, Ebneter A, et al. Aflibercept for age-related macular degeneration: 4-year outcomes of a ‘treat-and-extend’ regimen with exit-strategy. Br J Ophthalmol 2022;106:246-50.
crossref pmid pmc
18. Gascon P, Ramtohul P, Delaporte C, et al. Aflibercept in real-life for the treatment of age-related macular degeneration using a treat and extend protocol: the Armada study. Eur J Ophthalmol 2022;32:356-63.
crossref pmid pdf
19. Ishibashi K, Haruta M, Ishibashi Y, et al. Four-year outcomes of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a treat-and-extend regimen in Japanese patients. Ther Adv Ophthalmol 2021;13:2515841420984586.
crossref pmid pmc pdf
20. Maruko I, Ogasawara M, Yamamoto A, et al. Two-year outcomes of treat-and-extend intravitreal aflibercept for exudative age-related macular degeneration: a prospective study. Ophthalmol Retina 2020;4:767-76.
pmid
21. Jeong S, Ryu G, Sagong M. Modified observe-and-plan regimen using aflibercept for neovascular age-related macular degeneration. Acta Ophthalmol 2021;99:e1535-6.
crossref pmid pdf
22. Ohji M, Takahashi K, Okada AA, et al. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial. Adv Ther 2020;37:1173-87.
pmid pmc
23. Mitchell P, Holz FG, Hykin P, et al. Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration: the ARIES study: a randomized clinical trial. Retina 2021;41:1911-20.
pmid pmc
24. Chaikitmongkol V, Sagong M, Lai TY, et al. Treat-and-extend regimens for the management of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy: consensus and recommendations from the Asia-Pacific Vitreo-retina Society. Asia Pac J Ophthalmol (Phila) 2021;10:507-18.
crossref pmid pmc
25. Ohnaka M, Nagai Y, Sho K, et al. A modified treat-and-extend regimen of aflibercept for treatment-naïve patients with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2017;255:657-64.
crossref pmid pdf
26. Vofo BN, Cnaany Y, Chowers I. Clinical outcome using a modified treat-and-extend protocol for neovascular age-related macular degeneration. BMJ Open Ophthalmol 2022;7:e001180.
crossref pmid pmc
27. Charles J, Chau TT. Five-year outcome of aflibercept intra-vitreal injection in naïve patients with neovascular age-related macular degeneration using a modified treat-and-extend regimen: results from a prospective observational study. Taiwan J Ophthalmol 2023;13:219-24.
crossref pmid pmc
28. Mantel I, Niderprim SA, Gianniou C, et al. Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen. Br J Ophthalmol 2014;98:1192-6.
crossref pmid pmc
29. Parvin P, Zola M, Dirani A, et al. Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept. Graefes Arch Clin Exp Ophthalmol 2017;255:2127-34.
crossref pmid pmc pdf
30. Subhi Y, Schneider M, Hajari JN, la Cour M. Injection burden and treatment intervals of aflibercept in observe-and-plan regimen for neovascular age-related macular degeneration. Acta Ophthalmol 2024 May 11 [Epub]. https://doi.org/10.1111/aos.16709 .
crossref
31. Choi YJ, Yoo WS, Cho YW, et al. One-year outcomes of a treat-and-extend of ranibizumab for naive exudative age-related macular degeneration: retrospective analysis. J Korean Ophthalmol Soc 2021;62:939-47.
crossref pdf
32. Inoue M, Yamane S, Sato S, et al. Comparison of time to retreatment and visual function between ranibizumab and aflibercept in age-related macular degeneration. Am J Ophthalmol 2016;169:95-103.
crossref pmid
33. Kikushima W, Sakurada Y, Yoneyama S, et al. Incidence and risk factors of retreatment after three-monthly aflibercept therapy for exudative age-related macular degeneration. Sci Rep 2017;7:44020.
crossref pmid pmc pdf

Fig. 1
Flowchart for eyes included in the study. CDW = clinical data warehouse; nAMD = neovascular age-related macular degeneration; EMR = electronic medical records; AMD = age-related macular degeneration; VEGF = vascular endothelial growth factor; PDT = photodynamic therapy; O-TAE = observe before treat-and-extend.
kjo-2024-0083f1.jpg
Fig. 2
Best-corrected visual acuity (BCVA; mean ± standard deviation). logMAR = logarithm of minimal angle of resolution. *p < 0.05 (Wilcoxon signed rank test).
kjo-2024-0083f2.jpg
Fig. 3
Central macular thickness (CMT; mean ± standard deviation) *p < 0.05 (Wilcoxon signed rank test).
kjo-2024-0083f3.jpg
Fig. 4
Number of injections (mean ± standard deviation) administered in the first and second year. *p < 0.05 (Wilcoxon signed rank test).
kjo-2024-0083f4.jpg
Fig. 5
Proportion of treatment intervals in the first and second year of group A (treat-and-extend interval from a minimum of 8 weeks to a maximum of 12 weeks) and group B (treat-and-extend interval from a minimum of 4 weeks to a maximum of 16 weeks) combined.
kjo-2024-0083f5.jpg
Fig. 6
Schematic diagrams of the treatment protocol of the conventional treat-and-extend (TAE) and modified variations of the treatment regimen. (A) Conventional TAE. (B) Modified TAE. (C) Observe-and-plan. (D) Modified observe-and- plan. (E) Observe before TAE (this study). *An interval maintenance step (such as in ALTAIR) may be implemented, permitting tolerance of some residual subretinal fluid when vision has improved or remained stable and there are no signs of disease worsening (such as new subretinal hemorrhage). The possible treatment intervals for the fixed “treatment plan” ranged from a minimum of 1 month to a maximum of 3 months. Recurrences that were observed at 4 months or more since last injection, were an indication to treat every 3 months: the patient received the treatment plan of two injections every 3 months (2 × 3 months). Presented as “number of injections × fixed interval”: 3 × 1 month = three injections at fixed interval of 1 month and assessment visit 1 month after the third injection (total assessment interval 3 months); 3 × 1.5 month = three injections at fixed interval of 1.5 months and assessment visit 1.5 months after the third injection (total assessment interval 4.5 months); 3 × 2 months = three injections at fixed interval of 2 months and assessment visit 2 months after the third injection (total assessment interval 6 months); 2 × 2.5 months = two injections at fixed interval of 2.5 months and assessment visit 2.5 months after the second injection (total assessment interval 5 months); 2 × 3 months = two injections at fixed interval of 3 months and assessment visit 3 months after the second injection (total assessment interval 6 months).
kjo-2024-0083f6.jpg
Table 1
Baseline characteristics and demographics
Characteristic Value
No. of patients 34
No. of eyes 38
Follow-up period (mon) 37.0 ± 11.0 (24.0-61.6)
Age (yr) 72.0 ± 9.8
Sex (n = 34)
 Male 21 (61.8)
 Female 13 (38.2)
Laterality
 Right eye 17 (44.7)
 Left eye 21 (55.3)
Lens status
 Phakic 26 (68.4)
 Pseudophakic 12 (31.6)
BCVA (logMAR) 0.33 ± 0.29
Central macular thickness (μm) 357.43 ± 74.53
Type of nAMD
 Typical nAMD 28 (73.7)
 Polypoidal choroidal vasculopathy 10 (26.3)

Values are presented as number only, mean ± standard deviation (range), number (%), or mean ± standard deviation.

BCVA = best-corrected visual acuity; logMAR = logarithm of minimal angle of resolution; nAMD = neovascular age-related macular degeneration.

Table 2
BCVA by logMAR at each follow-up period
Period BCVA (logMAR) p-value*

Total (n = 38) Group A (n = 18) Group B (n = 11)
Baseline 0.33 ± 0.29 0.32 ± 0.34 0.35 ± 0.23 0.465
First year 0.24 ± 0.23 0.25 ± 0.24 0.23 ± 0.25 0.877
p-value 0.010 0.372 0.059
Second year 0.25 ± 0.22 0.27 ± 0.20 0.24 ± 0.27 0.550
p-value 0.054 0.653 0.169

Values are presented as mean ± standard deviation. Group A, treat-and-extend interval from a minimum of 8 weeks to a maximum of 12 weeks. Group B, treat-and-extend interval from a minimum of 4 weeks to a maximum of 16 weeks.

BCVA = best-corrected visual acuity; logMAR = logarithm of minimal angle of resolution.

* Mann-Whitney U-test (group A vs. group B);

Wilcoxon signed rank test (first or second year vs. baseline).

Table 3
Central macular thickness at each follow-up period
Period Central macular thickness (μm) p-value*

Total (n = 38) Group A (n = 18) Group B (n = 11)
Baseline 357.43 ± 74.53 364.82 ± 76.43 360.64 ± 93.37 0.853
First year 269.62 ± 48.12 266.53 ± 43.80 293.73 ± 58.54 0.122
p-value <0.001 0.001 0.005
Second year 279.14 ± 54.64 285.59 ± 59.06 295.18 ± 55.07 0.580
p-value <0.001 0.008 0.033

Values are presented as mean ± standard deviation. Group A, treat-and-extend interval from a minimum of 8 weeks to a maximum of 12 weeks. Group B, treat-and-extend interval from a minimum of 4 weeks to a maximum of 16 weeks.

* Mann-Whitney U-test (group A vs. group B);

Wilcoxon signed rank test (first or second year vs. baseline).

Table 4
Number of injections in the first and the second year
Period No. of injections p-value*

Total (n = 38) Group A (n = 18) Group B (n = 11)
First year 5.11 ± 1.69 5.94 ± 1.39 5.45 ± 1.37 0.387
Second year 3.84 ± 2.39 5.00 ± 1.03 5.09 ± 1.38 0.912
p-value <0.001 0.006 0.206

Values are presented as mean ± standard deviation. Group A, treat-and-extend interval from a minimum of 8 weeks to a maximum of 12 weeks. Group B, treat-and-extend interval from a minimum of 4 weeks to a maximum of 16 weeks.

* Mann-Whitney U-test (group . A vs group B);

Wilcoxon signed rank test(first year vs second year)

Table 5
Dry-up after three loading injections and recurrence after dry-up
Variable Value
Dry-up after three loading injections (n = 38)
 Yes 36 (94.7)
 No 2 (5.3)
Recurrence after dry-up (n = 36)
 Yes 28 (77.8)
  Recurrence time (mon) 6.5 ± 7.1 (1.9-34.3)
 No 8 (22.2)
  Follow-up period (mon) 29.7 ± 8.1 (22.3-46.9)

Values are presented as number (%) or mean ± standard deviation (range).

Table 6
Comparison of the conventional TAE and other modified variations of the treatment regimen
Regimen Study Treatment protocol Illustrative study No. of eyes Interval between third and fourth injection BCVA change at 1 yr (from baseline) No. of injections at 1 yr (mean ± SD) BCVA change at 2 yr (from baseline) No. of injections at 2 yr (from 1 yr) (mean ± SD)
Conventional TAE Ohji et al. [22] Fig. 6A Ohji et al. [22] 123 (2W) 8 wk +9.0 letters (ETDRS) 7.2 ± 0.9 +7.6 letters (ETDRS) 3.6 ± 1.6
Mitchell et al. [23]
Chaikitmongkol et al. [24] (ALTAIR study) 123 (4W) +8.4 letters (ETDRS) 6.9 ± 1.0 +6.1 letters (ETDRS) 3.7 ± 1.4
Modified TAE Ohnaka et al. [25] Fig. 6B* Ohnaka et al. [25] 36 Injection resumed when recurrence occurred −0.08 logMAR 4.5 ± 2.0 NA NA
Vofo et al. [26]
Charles and Chau [27]
Observe-and-plan Mantel et al. [28] Fig. 6C Parvin et al. [29] 112 Injection resumed when recurrence occurred +8.0 ± 12.0 letters (ETDRS) 8.7 ± 3.0 +6.2 ± 14.6letters (ETDRS) 6.3 ± 6.2
Parvin et al. [29]
Subhi et al. [30]
Modified observe-and- plan Jeong et al. [21] Fig. 6D Jeong et al. [21] 48 Injection resumed when recurrence occurred Early-recurrence group: −0.17 logMAR Early-recurrence group: 6.6 ± 0.5 NA NA
Late-recurrence group: −0.20 logMAR Late-recurrence group: 3.7 ± 0.8
Observe before TAE This study Fig. 6E This study 38 Injection resumed when recurrence occurred −0.09 logMAR 5.1 ± 1.7 −0.08
logMAR
3.8 ± 2.4

TAE = treat-and-extend; BCVA = best-corrected visual acuity; SD = standard deviation; 2W = 2-week adjustment group; 4W = 4-week adjustment group; ETDRS = Early Treatment Diabetic Retinopathy Study; logMAR = logarithm of minimal angle of resolution; NA = not applicable.

* The treatment protocol was slightly different for each study. Treatment protocol of the study by Ohnaka et al. [25] is presented in Fig. 6B;

The treatment protocol was slightly different for each study. Treatment protocol of the study by Mantel et al. [28] is presented in Fig. 6C.



ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
#1001, Jeokseon Hyundai BD
130, Sajik-ro, Jongno-gu, Seoul 03170, Korea
Tel: +82-2-2271-6788    Fax: +82-2-2277-5194    E-mail: kos@ijpnc.com                

Copyright © 2024 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next